Press Releases

Encouraging results from Daxas® pivotal phase III studies Core products with continuous strong growth Strong sales in most home markets New manufacturing strategy for improved competitiveness

Both 12-month pivotal studies in patients with symptomatic ChronicObstructive Pulmonary Disease (COPD) meet primary endpoints Data shows reductions in moderate and severe exacerbations requiring medical intervention Application for marketing authorisation in EU and US expected for 2009 Partnering process for commercialisation in the US will be initiated

New network structure for improved competitiveness European production from five centres of competence and five regional supply facilities to ensure high customer service level Nycomed in Denmark will focus on regional and local supply Negotiations to sell Finnish manufacturing facility

Strong sales in key home markets Core products continue to develop very well Veltuzumab in-licensing significantly strengthens pipeline Oncology sale successfully closed

Preclinical anti-cancer program sold to Bayer Schering Pharma Bayer Schering Pharma will assume full development and commercialization rights

Licensing agreement with Immunomedics Worldwide rights for veltuzumab in non-oncology indications and subcutaneous application First subcutaneous anti-CD20 tested in clinical trials Significant enhancement to Nycomed’s autoimmune and inflammation pipeline

Strategic decision to divest oncology projects Eight anti-cancer projects in preclinical stage and clinical phase I Martinsried based 4SC will assume full development and commercialization rights

Very satisfactory first quarter, despite lower sales Adjusted EBITDA increases due to lower costs Most home markets performed very well Major advancements in US out-licensing strategy Bradley Pharmaceuticals integration largely finalised Agreement with Zydus Cadila to shift API production to Indian joint venture

New leadership for Commercial Operations Nycomed today announced the appointment of Guido Oelkers as the new Executive Vice President Commercial Operations. It is planned that he joins Nycomed in September 2008. Based in Zurich, Guido Oelkers will be in charge of all Commercial Operations and its Area Managers, with the exception of Russia/CIS.

Joint venture contract with Zydus Cadila to be amended for the production of active pharmaceutical ingredients (API) Transfer of chemical production from facilities in Singen (Germany) and Linz (Austria) to India until 2011 Singen and Linz will focus on pharmaceutical production

Total net turnover increases by 3.0% to € 3,497.4 million 31.0% increase in adjusted EBITDA Instanyl™ filed for European approval Own Pantoprazole generic as response to US at-risk launch Major progress in US out-licensing strategy Acquisition of Bradley Pharmaceuticals successfully closed

Nycomed creates a leading specialty pharmaceutical player in dermatology Enhanced platform for in-licensing and co-promotion of dermatology products Combined US dermatology sales of $450 million

Legal counsel to be integral part of Executive Committee Nycomed’s Board of Directors has appointed Michael Kuner Executive Vice President Legal. He joins the company’s Executive Committee with immediate effect.

Own presence in Venezuela to further enhance strong Latin American presence -Nycomed strategy to participate in high-growth markets and offer licensing opportunities to partners Nycomed is about to establish its own marketing and sales organisation in Venezuela. With this, the company will operate from an own subsidiary in all four leading Latin American pharmaceutical markets, Mexico, Brazil, Venezuela and Argentina. This is part of Nycomed’s strategy to strengthen its presence in high-growth markets and offer licensing opportunities to partners. Venezuela is the third largest pharmaceutical market in Latin America, with a total value of US-$ 3 billion and annual growth of 29...

Own generic of Pantoprazole introduced to US market Move in response to at-risk launch of generic Pantoprazole in the United States Nycomed and Wyeth remain convinced of valididity and enforcability of their patent and continue to pursue litigation

Sepracor acquires exclusive development, marketing and commercialisation rights to the Ciclesonide franchise in the United States Ciclesonide is the active ingredient in the ALVESCO® Inhalation Aerosol for asthma and the Omnaris™ Nasal Spray for allergic rhinitis ALVESCO® and Omnaris™ are FDA-approved and are on track to be launched in 2008 Agreement is in alignment with Nycomed’s strategy to cooperate with the best partners for its key brands in the United States Partnership between Nycomed and Sepracor provides a good strategic fit for both companies

ALVESCO® (ciclesonide) Inhalation Aerosol approved by FDA for the maintenance and prophylactic treatment of asthma in patients 12 years of age and older ALVESCO® will be commercialised by U.S. partner

Surgical patch TachoSil® planned to enter US market with partner Baxter Important milestone for Nycomed’s partnership strategy for the US market